Literature DB >> 28560854

Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.

Corine de Jong1, Stefan Sanders1, Geert-Jan Creemers2, Artur M Burylo3, Margot Taks1, Jan H M Schellens4,5, Maarten J Deenen1,6.   

Abstract

In this report we describe a young patient diagnosed with bulky FIGO stage IIIb squamous cell cervix carcinoma with severe and irreversible nephropathy after three weekly low-doses of cisplatin. Besides several known risk factors such as hypomagnesemia and hypoalbuminemia, the patient also proved to be homozygously polymorphic for two polymorphisms within the COMT gene (c.615 + 310C>T and c.616-367C>T). As COMT polymorphism has been associated with cisplatin-induced ototoxicity, its effect on nephrotoxicity of cisplatin should be the subject of further investigation.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  cisplatin; genotyping; nephrotoxicity; pharmacogenomics

Mesh：

Substances：

Year:  2017        PMID： 28560854      PMCID： PMC5555872          DOI： 10.1111/bcp.13309

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  13 in total

1.  Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Ivana Sullivan; Juliana Salazar; Margarita Majem; Cinta Pallarés; Elisabeth Del Río; David Páez; Montserrat Baiget; Agustí Barnadas
Journal:  Cancer Lett       Date:  2014-07-25       Impact factor: 8.679

2.  Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma.

Authors:  Charles Lu; Margaret R Spitz; Hua Zhao; Qiong Dong; Mylene Truong; Joe Y Chang; George R Blumenschein; Waun K Hong; Xifeng Wu
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

3.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

4.  Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.

Authors:  Oscar Arrieta; Rosa M Michel Ortega; Geraldine Villanueva-Rodríguez; Maria G Serna-Thomé; Diana Flores-Estrada; Consuelo Diaz-Romero; Cindy M Rodríguez; Luis Martínez; Karla Sánchez-Lara
Journal:  BMC Cancer       Date:  2010-02-21       Impact factor: 4.430

5.  Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.

Authors:  A V Khrunin; A Moisseev; V Gorbunova; S Limborska
Journal:  Pharmacogenomics J       Date:  2009-09-29       Impact factor: 3.550

6.  Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Authors:  Colin J D Ross; Hagit Katzov-Eckert; Marie-Pierre Dubé; Beth Brooks; S Rod Rassekh; Amina Barhdadi; Yassamin Feroz-Zada; Henk Visscher; Andrew M K Brown; Michael J Rieder; Paul C Rogers; Michael S Phillips; Bruce C Carleton; Michael R Hayden
Journal:  Nat Genet       Date:  2009-11-08       Impact factor: 38.330

Review 7.  Cisplatin nephrotoxicity: a review.

Authors:  Xin Yao; Kessarin Panichpisal; Neil Kurtzman; Kenneth Nugent
Journal:  Am J Med Sci       Date:  2007-08       Impact factor: 2.378

Review 8.  Mechanisms of Cisplatin nephrotoxicity.

Authors:  Ronald P Miller; Raghu K Tadagavadi; Ganesan Ramesh; William Brian Reeves
Journal:  Toxins (Basel)       Date:  2010-10-26       Impact factor: 4.546

9.  Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.

Authors:  Yasuhiro Kidera; Hisato Kawakami; Tsutomu Sakiyama; Kunio Okamoto; Kaoru Tanaka; Masayuki Takeda; Hiroyasu Kaneda; Shin-ichi Nishina; Junji Tsurutani; Kimiko Fujiwara; Morihiro Nomura; Yuzuru Yamazoe; Yasutaka Chiba; Shozo Nishida; Takao Tamura; Kazuhiko Nakagawa
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971
View more
  1 in total

1.  Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients.

Authors:  Bram C Agema; Stijn L W Koolen; Mirjam de With; Nadia van Doorn; Niels Heersche; Esther Oomen-de Hoop; Sabine Visser; Joachim G J V Aerts; Sander Bins; Ron H N van Schaik; Ron H J Mathijssen
Journal:  Genes (Basel)       Date:  2020-03-27       Impact factor: 4.096
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.